NeoGenomics Inc Cash Flow Conversion Efficiency
NeoGenomics Inc cash flow conversion efficiency. Based on the latest financial reports, NeoGenomics Inc (NEO) has a cash flow conversion efficiency ratio of 0.025x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($19.96 Million) by net assets ($786.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NeoGenomics Inc (2000–2025)
Cash flow conversion efficiency of NeoGenomics Inc from 2000 to 2025. This chart illustrates how NeoGenomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of NeoGenomics Inc for real-time trading data and today's change.
NeoGenomics Inc Cash Flow Conversion Ratio Explained
NeoGenomics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NeoGenomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NeoGenomics Inc ranked by their cash flow conversion efficiency. Also see NEO market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Macrolink Real Estate Co Ltd
SHE:000620
|
0.010x |
|
Sumber Alfaria Trijaya Tbk
JK:AMRT
|
0.049x |
|
Navitas Semiconductor Corp
NASDAQ:NVTS
|
-0.040x |
|
Hufvudstaden AB (publ)
ST:HUFV-A
|
0.013x |
|
KEPCO Engineering & Construction
KO:052690
|
-0.010x |
|
Zhejiang Zhongjian Technology Co Ltd
SHE:002779
|
-0.031x |
|
Vera Therapeutics Inc
NASDAQ:VERA
|
-0.213x |
|
OPERAD.D.SIT.MEX.A1 -01
F:98Y
|
0.040x |
Annual Cash Flow Conversion Efficiency for NeoGenomics Inc (2000–2025)
The table below shows the annual cash flow conversion efficiency of NeoGenomics Inc from 2000 to 2025. Review NEO free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $836.56 Million | $5.23 Million | 0.006x | -19.68% |
| 2024-12-31 | $902.34 Million | $7.02 Million | 0.008x | +475.22% |
| 2023-12-31 | $941.54 Million | $-1.95 Million | -0.002x | +96.86% |
| 2022-12-31 | $998.02 Million | $-65.99 Million | -0.066x | -174.23% |
| 2021-12-31 | $1.11 Billion | $-26.72 Million | -0.024x | -1246.64% |
| 2020-12-31 | $694.29 Million | $1.46 Million | 0.002x | -95.43% |
| 2019-12-31 | $507.41 Million | $23.37 Million | 0.046x | -67.05% |
| 2018-12-31 | $320.44 Million | $44.79 Million | 0.140x | +59.26% |
| 2017-12-31 | $205.53 Million | $18.04 Million | 0.088x | -23.75% |
| 2016-12-31 | $186.60 Million | $21.48 Million | 0.115x | +328.69% |
| 2015-12-31 | $238.11 Million | $6.39 Million | 0.027x | -82.84% |
| 2014-12-31 | $60.41 Million | $9.45 Million | 0.156x | +52.52% |
| 2013-12-31 | $21.71 Million | $2.23 Million | 0.103x | +292.14% |
| 2012-12-31 | $9.22 Million | $-492.00K | -0.053x | -556.25% |
| 2011-12-31 | $5.90 Million | $69.00K | 0.012x | +101.79% |
| 2010-12-31 | $3.13 Million | $-2.05 Million | -0.655x | -146.19% |
| 2009-12-31 | $5.64 Million | $-1.50 Million | -0.266x | -188.57% |
| 2008-12-31 | $1.50 Million | $-138.31K | -0.092x | +91.90% |
| 2007-12-31 | $2.32 Million | $-2.64 Million | -1.138x | +91.06% |
| 2006-12-31 | $54.51K | $-693.78K | -12.727x | -1503.72% |
| 2005-12-31 | $-994.94K | $-902.05K | 0.907x | -41.22% |
| 2004-12-31 | $-426.65K | $-658.13K | 1.543x | +6.57% |
| 2003-12-31 | $-367.80K | $-532.37K | 1.447x | +108.78% |
| 2002-12-31 | $23.34K | $-384.80K | -16.483x | -2333.16% |
| 2001-12-31 | $-104.87K | $-77.41K | 0.738x | -47.98% |
| 2000-12-31 | $-124.84K | $-177.13K | 1.419x | -- |
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to dise… Read more